Variable | ORH N = 131 | MIRH N = 47 | P | ORH after PSM N = 60 | MIRH after PSM N = 37 | P | ||
---|---|---|---|---|---|---|---|---|
Gender (%) | Â | Â | 0.97 | Â | Â | 1 | ||
 Female | 59 (45%) | 22 (46.8%) |  | 27 (45%) | 17 (45.9%) |  | ||
 Male | 72 (55%) | 25 (53.2%) |  | 33 (55%) | 20 (54.1%) |  | ||
Age (years) | 58 [45–67] | 59 [47.5–67] | 0.88 | 59 [52.5–68.25] | 59 [52–67] | 0.80 | ||
BMI (kg/m2) | 25.3 [22.3–28.5] | 25.4 [22.5–27.3] | 0.80 | 25.2 [22.1–27.7] | 25.6 [22.5–27.1] | 0.84 | ||
Obesity (%) | 20 (17.4%) | 5 (11.9%) | 0.56 | 7 (13%) | 3 (9.4%) | 0.74 | ||
ASA (%) | Â | Â | 0.67 | Â | Â | 0.84 | ||
 1–2 | 108 (82.4%) | 37 (78.7%) |  | 48 (80%) | 31 (83.8%) |  | ||
 3 | 23 (17.6%) | 10 (21.3%) |  | 12 (20%) | 6 (16.2%) |  | ||
Cardiologic comorbities (%) | 13 (9.9%) | 3 (6.4%) | 0.57 | 7 (11.7%) | 2 (5.4%) | 0.48 | ||
Pulmonary comorbities (%) | 4 (3.1%) | 2 (4.3%) | 0.66 | 2 (3.3%) | 2 (5.4%) | 0.63 | ||
Cirrhosis (%) | 11 (8.4%) | 11 (23.4%) | 0.02 | 7 (11.7%) | 7 (18.9%) | 0.49 | ||
Diagnostic (%) | Â | Â | 0.06 | Â | Â | 0.87 | ||
Benign | 17 (13%) | 9 (19.1%) | Â | 9 (15%) | 7 (18.9%) | Â | ||
Metastasis | 87 (66.4%) | 23 (48.9%) | Â | 33 (55%) | 19 (51.4%) | Â | ||
Malignant | 26 (19.8%) | 15 (31.9%) | Â | 18 (30%) | 11 (29.7%) | Â | ||
Nodules (%) | Â | Â | 0.03 | Â | Â | 0.95 | ||
 1 | 41 (35.7%) | 7 (15.9%) |  | 13 (21.7%) | 7 (18.9%) |  | ||
 2–3 | 52 (45.2%) | 23 (52.3%) |  | 33 (55%) | 21 (56.8%) |  | ||
 ≥ 4 | 22 (19.1%) | 14 (31.8%) |  | 14 (23.3%) | 9 (24.3%) |  | ||
Previous abdominal surgery (%) | 100 (76.3%) | 20 (42.6%) | < 0.0001 | 36 (60%) | 18 (48.6%) | 0.38 | ||
Chemotherapy (%) | 77 (59.2%) | 20 (42.6%) | 0.07 | 28 (46.7%) | 16 (43.2%) | 0.91 | ||
PVE (%) | 24 (18.3%) | 11 (23.4%) | 0.59 | 12 (20%) | 9 (24.3%) | 0.80 |